D. Wingerchuk, W. Hogancamp, O. Brien, P. Weinshenker, and B. , The clinical course of neuromyelitis optica (Devic's syndrome), Neurology, vol.53, issue.5, p.110714, 1999.
DOI : 10.1212/WNL.53.5.1107

M. Papadopoulos and A. Verkman, Aquaporin 4 and neuromyelitis optica, The Lancet Neurology, vol.11, issue.6, p.53544, 2012.
DOI : 10.1016/S1474-4422(12)70133-3

S. Jarius, B. Wildemann, and F. Paul, Neuromyelitis optica: clinical features, immunopathogenesis and treatment, Clinical & Experimental Immunology, vol.260, issue.2, p.14964, 2014.
DOI : 10.1111/cei.12271

L. Pandit, N. Asgari, M. Apiwattanakul, J. Palace, F. Paul et al., Demographic and clinical features of neuromyelitis optica: A review, Multiple Sclerosis Journal, vol.21, issue.7, p.84553, 2015.
DOI : 10.1212/WNL.0b013e3181ea9f15

N. Collongues, R. Marignier, H. Zéphir, C. Papeix, F. Blanc et al., Neuromyelitis optica in France: A multicenter study of 125 patients, Neurology, vol.74, issue.9, p.73642, 2010.
DOI : 10.1212/WNL.0b013e3181d31e35

D. Wingerchuk, V. Lennon, C. Lucchinetti, S. Pittock, and B. Weinshenker, The spectrum of neuromyelitis optica, The Lancet Neurology, vol.6, issue.9, p.80515, 2007.
DOI : 10.1016/S1474-4422(07)70216-8

V. Lennon, T. Kryzer, S. Pittock, A. Verkman, and S. Hinson, IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel, The Journal of Experimental Medicine, vol.43, issue.4, p.4737, 2005.
DOI : 10.1523/JNEUROSCI.1485-04.2004

T. Takahashi, K. Fujihara, I. Nakashima, T. Misu, I. Miyazawa et al., Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre, Brain, vol.130, issue.5, p.123543, 2007.
DOI : 10.1093/brain/awm062

T. Misu, K. Fujihara, A. Kakita, H. Konno, M. Nakamura et al., Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis, Brain, vol.130, issue.5, p.122434, 2007.
DOI : 10.1093/brain/awm047

B. Popescu, V. Lennon, J. Parisi, C. Howe, S. Weigand et al., Neuromyelitis optica unique area postrema lesions: Nausea, vomiting, and pathogenic implications, Neurology, vol.76, issue.14, p.122937, 2011.
DOI : 10.1212/WNL.0b013e318214332c

S. Jarius, K. Ruprecht, B. Wildemann, T. Kuempfel, M. Ringelstein et al., Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients, Journal of Neuroinflammation, vol.76, issue.Pt 1, p.14, 2012.
DOI : 10.1186/1742-2094-9-14

S. Jarius and B. Wildemann, AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance, Nature Reviews Neurology, vol.55, issue.7, p.38392, 2010.
DOI : 10.1038/nrneurol.2010.72

J. Ratelade and A. Verkman, Neuromyelitis optica: Aquaporin-4 based pathogenesis mechanisms and new therapies, The International Journal of Biochemistry & Cell Biology, vol.44, issue.9, p.151930, 2012.
DOI : 10.1016/j.biocel.2012.06.013

W. Pereira, C. Reiche, E. Kallaur, A. Kaimen-maciel, and D. , Epidemiological, clinical, and immunological characteristics of neuromyelitis optica: A review, Journal of the Neurological Sciences, vol.355, issue.1-2, p.717, 2015.
DOI : 10.1016/j.jns.2015.05.034

P. Phuan, J. Ratelade, A. Rossi, L. Tradtrantip, and A. Verkman, Complement-dependent Cytotoxicity in Neuromyelitis Optica Requires Aquaporin-4 Protein Assembly in Orthogonal Arrays, Journal of Biological Chemistry, vol.287, issue.17, p.1382939, 2012.
DOI : 10.1074/jbc.M112.344325

J. Goverman, Autoimmune T cell responses in the central nervous system, Nature Reviews Immunology, vol.30, issue.6, p.393407, 2009.
DOI : 10.1038/nri2550

A. Uzawa, M. Mori, K. Arai, Y. Sato, S. Hayakawa et al., Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6, Multiple Sclerosis Journal, vol.115, issue.12, p.144352, 2010.
DOI : 10.1002/(SICI)1521-4141(199807)28:07<2178::AID-IMMU2178>3.0.CO;2-D

D. Zhang, K. Jia, R. Wang, T. Li, N. Zhao et al., Decreased serum IL-27 and IL-35 levels are associated with disease severity in neuromyelitis optica spectrum disorders, Journal of Neuroimmunology, vol.293, p.1004, 2016.
DOI : 10.1016/j.jneuroim.2016.03.004

J. Lin, X. Li, and J. Xia, Th17 cells in neuromyelitis optica spectrum disorder: a review, International Journal of Neuroscience, vol.17, issue.1, 2016.
DOI : 10.2967/jnumed.111.102608

C. Lucchinetti, Y. Guo, B. Popescu, K. Fujihara, Y. Itoyama et al., The Pathology of an Autoimmune Astrocytopathy: Lessons Learned from Neuromyelitis Optica, Brain Pathology, vol.27, issue.1, p.8397, 2014.
DOI : 10.1111/bpa.12099

C. González, J. González-buitrago, and G. Izquierdo, Aquaporins, anti-aquaporin-4 autoantibodies and neuromyelitis optica, Clinica Chimica Acta, vol.415, p.35060, 2013.
DOI : 10.1016/j.cca.2012.04.027

J. Sellner, B. Hemmer, and M. Mühlau, The clinical spectrum and immunobiology of parainfectious neuromyelitis optica (Devic) syndromes, Journal of Autoimmunity, vol.34, issue.4, p.3719, 2010.
DOI : 10.1016/j.jaut.2009.09.013

H. Zéphir, I. Fajardy, O. Outteryck, F. Blanc, N. Roger et al., Is neuromyelitis optica associated with human leukocyte antigen? Mult Scler Houndmills Basingstoke Engl, p.5719, 2009.

Y. Blanco, G. Ercilla-gonzález, S. Llufriu, B. Casanova-estruch, M. Magraner et al., HLA-DRB1 typing in Caucasians patients with neuromyelitis optica], Rev Neurol. 1 août, vol.53, issue.3, p.14652, 2011.

R. Deschamps, L. Paturel, S. Jeannin, N. Chausson, S. Olindo et al., Different HLA class II (DRB1 and DQB1) alleles determine either susceptibility or resistance to NMO and multiple sclerosis among the French Afro-Caribbean population, Multiple Sclerosis Journal, vol.189, issue.1, p.2431, 2011.
DOI : 10.1371/journal.pgen.0030150

M. Matiello, V. Lennon, A. Jacob, S. Pittock, C. Lucchinetti et al., NMO-IgG predicts the outcome of recurrent optic neuritis, Neurology, vol.70, issue.23, p.2197200, 2008.
DOI : 10.1212/01.wnl.0000303817.82134.da

M. Bradl, T. Misu, T. Takahashi, M. Watanabe, S. Mader et al., Neuromyelitis optica: Pathogenicity of patient immunoglobulin in vivo, Annals of Neurology, vol.66, issue.5, p.63043, 2009.
DOI : 10.1002/ana.21837

R. Marignier, A. Nicolle, C. Watrin, M. Touret, S. Cavagna et al., Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury, Brain, vol.133, issue.9, p.257891, 2010.
DOI : 10.1093/brain/awq177

M. Mitsdoerffer, V. Kuchroo, and T. Korn, Immunology of neuromyelitis optica: a T cell-B cell collaboration, Annals of the New York Academy of Sciences, vol.70, issue.1, p.5766, 2013.
DOI : 10.1111/nyas.12118

D. Sato, D. Callegaro, M. Lana-peixoto, I. Nakashima, and K. Fujihara, Seronegative Neuromyelitis Optica Spectrum - The challenges on disease definition and pathogenesis, Arquivos de Neuro-Psiquiatria, vol.72, issue.6, p.44550, 2014.
DOI : 10.1590/0004-282X20140032

S. Pittock, V. Lennon, J. De-seze, P. Vermersch, H. Homburger et al., Neuromyelitis Optica and Non???Organ-Specific Autoimmunity, Archives of Neurology, vol.65, issue.1, p.7883, 2008.
DOI : 10.1001/archneurol.2007.17

V. Lennon, D. Wingerchuk, T. Kryzer, S. Pittock, C. Lucchinetti et al., A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis, The Lancet, vol.364, issue.9451, p.210612, 2004.
DOI : 10.1016/S0140-6736(04)17551-X

P. Waters, A. Mckeon, M. Leite, S. Rajasekharan, V. Lennon et al., Serologic diagnosis of NMO: A multicenter comparison of aquaporin-4-IgG assays, Neurology, vol.78, issue.9, p.665671, 2012.
DOI : 10.1212/WNL.0b013e318248dec1

R. Marignier, R. Bernard-valnet, P. Giraudon, N. Collongues, C. Papeix et al., Aquaporin-4 antibody-negative neuromyelitis optica: Distinct assay sensitivity-dependent entity, Neurology, vol.80, issue.24, p.2194200, 2013.
DOI : 10.1212/WNL.0b013e318296e917

J. Fryer, V. Lennon, S. Pittock, S. Jenkins, P. Fallier-becker et al., AQP4 autoantibody assay performance in clinical laboratory service, Neurology - Neuroimmunology Neuroinflammation, vol.1, issue.1, p.11, 2014.
DOI : 10.1212/NXI.0000000000000011

K. Chan, C. Tse, C. Chung, R. Lee, J. Kwan et al., Brain Involvement in Neuromyelitis Optica Spectrum Disorders, Archives of Neurology, vol.68, issue.11, p.14329, 2011.
DOI : 10.1001/archneurol.2011.249

S. Pittock, V. Lennon, K. Krecke, D. Wingerchuk, C. Lucchinetti et al., Brain Abnormalities in Neuromyelitis Optica, Archives of Neurology, vol.63, issue.3, p.3906, 2006.
DOI : 10.1001/archneur.63.3.390

S. Pittock, B. Weinshenker, C. Lucchinetti, D. Wingerchuk, J. Corboy et al., Neuromyelitis Optica Brain Lesions Localized at Sites of High Aquaporin 4 Expression, Archives of Neurology, vol.63, issue.7, p.9648, 2006.
DOI : 10.1001/archneur.63.7.964

H. Kim, F. Paul, M. Lana-peixoto, S. Tenembaum, N. Asgari et al., MRI characteristics of neuromyelitis optica spectrum disorder: An international update, Neurology, vol.84, issue.11, p.116573, 2015.
DOI : 10.1212/WNL.0000000000001367

D. Wingerchuk, V. Lennon, S. Pittock, C. Lucchinetti, and B. Weinshenker, Revised diagnostic criteria for neuromyelitis optica, American Journal of Ophthalmology, vol.142, issue.4, p.14859, 2006.
DOI : 10.1016/j.ajo.2006.08.010

S. Magaña, M. Matiello, S. Pittock, A. Mckeon, V. Lennon et al., Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders, Neurology, vol.72, issue.8, p.7127, 2009.
DOI : 10.1212/01.wnl.0000343001.36493.ae

D. Wingerchuk, B. Banwell, J. Bennett, P. Cabre, W. Carroll et al., International consensus diagnostic criteria for neuromyelitis optica spectrum disorders, Neurology, vol.85, issue.2, p.17789, 2015.
DOI : 10.1212/WNL.0000000000001729

D. Sato, D. Callegaro, M. Lana-peixoto, I. Nakashima, and K. Fujihara, Seronegative Neuromyelitis Optica Spectrum - The challenges on disease definition and pathogenesis, Arquivos de Neuro-Psiquiatria, vol.72, issue.6, p.44550, 2014.
DOI : 10.1590/0004-282X20140032

C. Trebst, S. Jarius, A. Berthele, F. Paul, S. Schippling et al., Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS), J Neurol. janv, vol.261, issue.1, p.116, 2014.

Y. Jiao, J. Fryer, V. Lennon, A. Mckeon, S. Jenkins et al., Aquaporin 4 IgG Serostatus and Outcome in Recurrent Longitudinally Extensive Transverse Myelitis, JAMA Neurology, vol.71, issue.1, p.4854, 2014.
DOI : 10.1001/jamaneurol.2013.5055

M. Mealy, D. Wingerchuk, J. Palace, B. Greenberg, and M. Levy, Comparison of Relapse and Treatment Failure Rates Among Patients With Neuromyelitis Optica, JAMA Neurology, vol.71, issue.3, p.32430, 2014.
DOI : 10.1001/jamaneurol.2013.5699

H. Zhang and A. Verkman, Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica, Journal of Clinical Investigation, vol.123, issue.5, p.230616, 2013.
DOI : 10.1172/JCI67554

S. Pittock, V. Lennon, A. Mckeon, J. Mandrekar, B. Weinshenker et al., Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study, The Lancet Neurology, vol.12, issue.6, p.55462, 2013.
DOI : 10.1016/S1474-4422(13)70076-0

I. Kleiter and R. Gold, Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders, Neurotherapeutics, vol.84, issue.1, p.7083, 2016.
DOI : 10.1007/s00415-015-7952-8

B. Weinshenker, D. Wingerchuk, S. Pittock, C. Lucchinetti, and V. Lennon, NMO-IgG: A Specific Biomarker for Neuromyelitis Optica, Disease Markers, vol.22, issue.4, p.197206, 2006.
DOI : 10.1155/2006/586306

E. Flanagan, B. Weinshenker, K. Krecke, V. Lennon, C. Lucchinetti et al., Short Myelitis Lesions in Aquaporin-4-IgG???Positive Neuromyelitis Optica Spectrum Disorders, JAMA Neurology, vol.72, issue.1, p.817, 2015.
DOI : 10.1001/jamaneurol.2014.2137

I. Pirko, L. Blauwet, L. Blauwet, T. Lesnick, and B. Weinshenker, The Natural History of Recurrent Optic Neuritis, Archives of Neurology, vol.61, issue.9, p.14015, 2004.
DOI : 10.1001/archneur.61.9.1401

S. Ramanathan, R. Dale, and F. Brilot, Anti-MOG antibody: The history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination, Autoimmunity Reviews, vol.15, issue.4, 2015.
DOI : 10.1016/j.autrev.2015.12.004

A. Mckeon, V. Lennon, A. Jacob, M. Matiello, C. Lucchinetti et al., Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica, Muscle & Nerve, vol.66, issue.1, p.8790, 2009.
DOI : 10.1002/mus.21197

Y. Jiao, J. Fryer, V. Lennon, S. Jenkins, A. Quek et al., Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica, Neurology, vol.81, issue.14, p.1197204, 2013.
DOI : 10.1212/WNL.0b013e3182a6cb5c

S. Ramanathan, K. Prelog, E. Barnes, E. Tantsis, S. Reddel et al., Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis, Multiple Sclerosis Journal, vol.22, issue.4, 2015.
DOI : 10.1186/2051-5960-2-35

D. Sato, D. Callegaro, M. Lana-peixoto, P. Waters, F. De-haidar-jorge et al., Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders, Neurology, vol.82, issue.6, p.47481, 2014.
DOI : 10.1212/WNL.0000000000000101

S. Zamvil and A. Slavin, Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder?, Neurology - Neuroimmunology Neuroinflammation, vol.2, issue.1, p.62, 2015.
DOI : 10.1212/NXI.0000000000000062

S. Kim, M. Woodhall, J. Kim, S. Kim, K. Park et al., Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS, Neurology - Neuroimmunology Neuroinflammation, vol.2, issue.6, p.163, 2015.
DOI : 10.1212/NXI.0000000000000163

I. Nakashima, T. Takahashi, B. Cree, H. Kim, C. Suzuki et al., Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels, Journal of Clinical Neuroscience, vol.18, issue.7, p.9978, 2011.
DOI : 10.1016/j.jocn.2010.12.011

M. Majed, J. Fryer, A. Mckeon, V. Lennon, and S. Pittock, Clinical utility of testing AQP4-IgG in CSF, Neurology - Neuroimmunology Neuroinflammation, vol.3, issue.3, p.231, 2016.
DOI : 10.1212/NXI.0000000000000231